3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
6
Carcinoid Tumor
5
Neoplasms
4
Carcinoma
3
Vipoma
2
Neoplasm Metastasis
2
Intestinal Obstruction
2
Carcinoma, Islet Cell
2
Somatostatinoma
1
Recurrence
1
Prostatic Neoplasms
1
Primary Inoperable Thymoma
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Malignant Carcinoid Syndrome
1
Lymphangiomyoma
1
Lymphangioleiomyomatosis
1
Insulinoma
1
Glucagonoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastrinoma
1
Diarrhea
1
Chylous Ascites
1
Chylothorax
1
Carcinoma, Neuroendocrine
1
Breast Neoplasms
1
Ascites
1
Adenoma, Islet Cell
1
Interventions
Octreotide
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Malignant Carcinoid Syndrome
×
Octreotide
×
Clear all
NCT00412061
2014-11-21
RADIANT-2
Novartis
Phase 3
Completed
429 enrolled
13 charts